Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

Weight-loss drugs fuel boom for firms that fill syringes

Catalent's automated visual inspection systems that check every pre-filled syringe to ensure pr... Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Catalent/Handout via REUTERS
Catalent's automated visual inspection systems that check every pre-filled syringe to ensure pr... Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Catalent/Handout via REUTERS

Listen to the article now

Weight-loss drugs fuel boom for firms that fill syringes. Contract pharma makers are spending billions of dollars to develop or construct facilities that fill the injectable pens used to give treatments like Novo Nordisk’s (NOVOb.CO) Wegovy to capitalize on the rising demand for weight-loss medications.

Interviews with a dozen business executives, analysts, and investors revealed that pharmaceutical service providers are vying for more specialized fill-finish work—filling the syringes used in the pens.

Tejas Savant, the senior healthcare equities analyst at Morgan Stanley, stated, “Every contract manufacturer with sterile fill-finish capacity wants to add more, to get ahead, because it’s not just about Wegovy anymore.” “You also have Lilly’s Mounjaro coming and others.”

Since its introduction in the United States in June 2021, sales of Wegovy, the first of a new series of obesity therapies that imitate the body’s appetite-suppressing hormones, have skyrocketed. This year, the United States is anticipated to approve Eli Lilly’s (LLY.N) Mounjaro for weight reduction.

The weekly weight-loss injections are a member of the GLP-1 agonist medicine class, which experts predict would reach a market value of $100 billion within ten years and include the oral therapies now being investigated by Pfizer (PFE.N) and other companies. According to Chris Chen, CEO of WuXi Biologics (2269. HK), his business is in discussions with clients about using the pre-filled syringe capacity it is constructing at a German plant it acquired in 2020.

He described interest as being “pretty high” and stated that he plans to purchase other plants in Europe to service GLP-1 clients, but he did not provide any further information. According to Cornell Stamoran, vice president of corporate strategy and government affairs at Catalent, the company is increasing “significant” pre-filled syringe capacity at its plants in Anagni, Italy, and Bloomington, Indiana, in the United States. In 2024, they will go online.

The American business already performs fill-finish work for Wegovy. Contract development and manufacturing organizations (CDMOs) started competing for business last year. Since then, other ventures, including Lonza (LONN.S), Fujifilm Diosynth Biotechnologies, a division of Fujifilm Corp., and Germany’s Vetter, have launched initiatives totaling at least $3 billion.

The pace is quickening as Lilly gears up to introduce Mounjaro, and Novo struggles to keep up with demand even as it expands the availability of Wegovy in new areas.

According to CEO Marc Casper, another Novo partner, Thermo Fisher (TMO.N), is transforming facilities to fill COVID-19 vaccination syringes to handle pens for obesity and diabetes medications.

He said that there was a severe capacity deficit. A firm representative declined to respond. All of the businesses contacted by Reuters declined to provide details about possible clients or contracts.

BETWEEN COVID AND OBESITY

When large pharmaceutical companies lack internal size or competence, they employ CDMOs. Before the assembly and packaging of pens and their subsequent shipment by wholesalers to pharmacies and clinics, syringes are filled in sterile conditions to prevent contamination.

With plans to open other contract manufacturing facilities besides the three managed by Catalent and Thermo, Novo is investing billions to boost production at its own Wegovy plant.

Still, shortages would persist until the next year. Lilly is also expanding its internal capabilities, although, at this time, a spokesman said, it employs an “extensive portfolio” of CDMOs; compared to Wegovy, Mounjaro’s medication trials showed more effectiveness.

The fill-finish industry is expected to more than quadruple to $12.5 billion between 2019 and 2027, according to research company The Insight Partners. A business expert says that is almost twice as fast as pills or capsules.

Fresh GLP-Executives said that one firm could more than make up for the lost COVID-19 vaccination contracts.

The development of biological medications, some of which are injected, is also being accelerated under the U.S. Inflation Reduction Act. Many new Alzheimer’s and generic arthritis medications are injected, and injectables are used more often in settings where older people get care.

GLP-1s, however, are the main driver of investments, according to the firms. Given that many projects won’t be finished until 2019 or, in some circumstances, 2026, supply shortages are expected to continue. According to a healthcare investor, how quickly the market for obesity drugs expands will depend on CDMOs’ capacity expansion.

Because of their current capabilities, Catalent and Thermo are “in the catbird seat” dominating the industry in the interim, according to Barclays analyst Luke Sergott. According to LSEG statistics, Catalent shares are trading 42 times predicted earnings over the next 12 months, greater than Lonza’s and Thermo’s multiples of 28 and 21, respectively. This reflects Catalent’s leadership in the obesity market despite certain quality difficulties. According to Reuters in July, wegovy shortages were reportedly brought on by quality issues at Catalent’s Brussels manufacturing.

Executives said there wouldn’t be a surplus due to the capacity race. “Based on my 30 years in the field, CDMOs don’t operate under the ‘build it, and they will come’ theory. That’s not how you create a CDMO company that will endure, according to Stamoran of Catalent.


Comment Template

You May Also Like

Business

MSG Networks has returned to Optimum after a nearly two-month blackout, restoring Knicks and Rangers coverage for frustrated fans. The new deal places MSG...

Business

Alphabet has introduced **Premium Lite**, a lower-cost YouTube subscription offering ad-free videos (excluding music). This move aims to expand YouTube’s subscriber base and reduce...

Business

India has been named the best solo travel destination for 2025 by Kensington, thanks to its rich culture, history, and diverse experiences. From the...

Business

Warren Buffett's Berkshire Hathaway has aggressively sold stocks, amassing a record $334 billion in cash. Major divestments include Apple and Bank of America, while...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok